Company Overview
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Why Investors Should Care
Revenue has grown at a 28.3% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $21.05M (-79.1% YoY); net profit $-142.93M.
- Trailing 12 Months Year-on-year growth — revenue -57.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 28.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 28.27% |
| 1 Year: | -57.80% |
Stock Price Performance
| 1 Year: | -16.06% |
| 6 Months: | -24.07% |
| 3 Months: | +21.19% |
| 1 Month: | -4.69% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.77 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 28.3% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 44.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ALEC Alector, Inc. R2KR3KPHARMA | 1.83 | -1.68 | $204.33M | 0.00% | -69.73% | - | 28.27% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.75M | 7.11M | 6.50M | - | 5.61M | 6.92M | 2.70M | - | 7.17M | 3.17M | 5.90M | 4.11M | 6.57M | 182.41M | 24.47M | 79.85M | 14.85M | 16.55M | 56.21M | 9.11M | 15.89M | 15.08M | 15.34M | 3.67M | 7.87M | 3.26M | 6.24M | 1.05M | 3.32M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 48.37M | 42.01M | 40.87M | 45.80M | 25.96M | - |
| Operating Income | -9.22M | -12.23M | -16.82M | -19.02M | -20.76M | -27.15M | -34.15M | -32.34M | -42.08M | -46.59M | -53.75M | -52.63M | -55.33M | 126.33M | -44.12M | 9.47M | -47.75M | -50.12M | -3.59M | -50.58M | -43.71M | -45.61M | -48.43M | -44.70M | -34.14M | -37.61M | -39.57M | -24.92M | -24.39M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -42.85M | -30.92M | -35.28M | -37.31M | -22.84M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -40.47M | -30.52M | -34.67M | -37.10M | -22.93M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 168.00K | 0 | - |
| Net Income | -8.44M | -11.12M | -15.32M | -17.37M | -18.56M | -24.56M | -31.74M | -30.53M | -40.02M | -45.33M | -52.70M | -52.17M | -55.15M | 126.60M | -44.62M | 9.88M | -46.15M | -45.86M | 1.38M | -44.48M | -36.08M | -38.68M | -42.22M | -40.47M | -30.52M | -34.67M | -37.27M | -22.93M | -22.99M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.67 | - | -0.69 | 1.49 | -0.54 | 0.12 | -0.56 | -0.55 | 0.02 | -0.53 | -0.38 | -0.40 | -0.43 | -0.41 | -0.30 | -0.34 | -0.34 | -0.21 | -0.21 |
| R&D Expense | 11.72M | 16.82M | 20.39M | - | 20.61M | 25.64M | 28.52M | - | 34.60M | 34.06M | 43.82M | 45.73M | 47.82M | 43.07M | 53.04M | 54.53M | 48.35M | 51.89M | 46.18M | 46.33M | 45.17M | 46.31M | 48.00M | 33.64M | 27.61M | 29.35M | - | 17.86M | 19.46M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.87M | 27.51M | 21.22M | 21.10M | 207.09M | 133.62M | 97.06M | 100.56M | 21.05M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 271.45M | 248.80M | 245.56M | 177.05M |
| Operating Income | -32.68M | -57.29M | -114.40M | -195.17M | -37.36M | -137.83M | -151.74M | -145.00M | -156.01M |
| EBITDA | - | - | - | - | - | -129.36M | -142.89M | -136.16M | -146.35M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | -130.06M | -125.18M | -118.92M | -142.76M |
| Tax Provision | - | - | - | - | - | 3.25M | 5.21M | 128.00K | 168.00K |
| Net Income | -32.48M | -52.25M | -105.39M | -190.23M | -36.33M | -133.31M | -130.39M | -119.05M | -142.93M |
| Diluted EPS | - | - | - | -2.45 | -0.45 | -1.62 | -1.56 | -1.23 | -1.39 |
| R&D Expense | 29.91M | 73.03M | 100.53M | 156.87M | 189.41M | 210.42M | 192.12M | 185.94M | 123.06M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 308.36M | 421.91M | 488.25M | - | 787.65M | 621.83M | 468.30M | 293.24M |
| Current Assets | - | - | - | - | - | - | 726.43M | 565.81M | 424.82M | 266.45M |
| Cash & Equivalents | - | 32.45M | 65.47M | 89.64M | 49.97M | - | 154.32M | 74.56M | 33.02M | 65.80M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | 7.39M | 2.59M | 0 | - | - |
| Total Liabilities | - | - | 195.24M | 227.17M | 220.72M | - | 573.21M | 487.67M | 341.50M | 262.59M |
| Current Liabilities | - | - | 47.95M | 61.97M | 68.09M | - | 93.81M | 177.95M | 125.06M | 69.50M |
| Long Term Debt | - | - | - | - | - | - | - | - | 9.39M | 9.32M |
| Total Debt | - | - | - | - | - | - | 43.33M | 38.92M | 42.52M | 36.23M |
| Total Equity | -24.91M | -52.03M | -97.40M | 194.74M | 267.53M | - | 214.44M | 134.16M | 126.80M | 30.65M |
| Shares Outstanding | - | - | - | - | - | - | 82.90M | 84.88M | 99.09M | 110.36M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -17.77M | 127.46M | -99.31M | -166.73M | - | -20.33M | -184.16M | -229.91M | -184.03M |
| Investing Cash Flow | -801.00K | -224.12M | -48.87M | -105.05M | - | -159.01M | 101.92M | 107.13M | 196.60M |
| Financing Cash Flow | -15.00K | 131.15M | 172.35M | 232.11M | - | 4.51M | 2.55M | 81.54M | 20.21M |
| Capital Expenditure | -801.00K | -1.88M | -15.27M | -5.03M | - | -4.12M | -2.38M | -1.25M | -41.00K |
| Free Cash Flow | -18.57M | 125.58M | -114.57M | -171.77M | - | -24.45M | -186.54M | -231.16M | -184.07M |
| Net Change in Cash | - | - | - | - | - | -174.83M | -79.69M | -41.23M | 32.78M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -1,137.8% | -208.3% | -539.2% | -925.1% | -18.0% | -103.2% | -156.3% | -144.2% | -741.3% |
| Net Margin % | -1,130.9% | -189.9% | -496.7% | -901.6% | -17.5% | -99.8% | -134.3% | -118.4% | -679.2% |
| ROE % | 62.4% | 53.6% | -54.1% | -71.1% | - | -62.2% | -97.2% | -93.9% | -466.3% |
| ROCE % | - | -22.0% | -31.8% | -46.5% | - | -19.9% | -34.2% | -42.2% | -69.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | TCG Crossover Management, LLC | 8.96% | 10.00M | $20.80M |
| 2 | Blackrock Inc. | 7.03% | 7.85M | $16.32M |
| 3 | Acadian Asset Management. LLC | 3.95% | 4.41M | $9.18M |
| 4 | Nantahala Capital Management, LLC | 3.87% | 4.32M | $8.98M |
| 5 | Vanguard Capital Management LLC | 3.59% | 4.01M | $8.34M |
| 6 | Kynam Capital Management, LP | 3.41% | 3.81M | $7.92M |
| 7 | Merck & Co., Inc. | 3.18% | 3.55M | $7.38M |
| 8 | Balyasny Asset Management LP | 2.91% | 3.25M | $6.75M |
| 9 | 683 Capital Management LLC | 2.87% | 3.20M | $6.66M |
| 10 | Shaw D.E. & Co., Inc. | 2.65% | 2.96M | $6.16M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ALEC
Alector stock surges 13% on premium-priced equity offering
Investing.com -- Alector shares surged about 13% in premarket trading Friday following the company’s announcement of a $75 million stock offering priced at a premium to the previous day’s close.
Alector Announces Pricing of Underwritten Offering
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (“Alector,” Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced …
Alector (ALEC) Stock Fair Value Rises After Genentech Deal Draws Split Analyst Views
Alector’s internal fair value estimate has shifted from US$3.10 to US$3.90 per share, which places it in the lower half of the current analyst price target range. This updated view sits alongside external targets that cluster between roughl…
Alector Maps Brain-Delivery Pipeline for Alzheimer’s, Parkinson’s Therapies
Alector (NASDAQ:ALEC) outlined its strategy to advance brain-penetrant therapies for neurodegenerative diseases, highlighting an anti-amyloid beta antibody for Alzheimer’s disease and two siRNA programs targeting tau and alpha-synuclein. Ch…
Stocktwits Biotech Dealmaker — Viatris And GE Healthcare Buy What They Can Sell; Biohaven And Alector Sell Rights
Drugmakers this week did not purchase experimental drug candidates but invested in approved drugs and a factory that makes imaging agents.
Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline
Agenda to feature progress for AL137, its lead anti-amyloid beta antibody; AL164, its tau siRNA program; and AL062, its alpha-synuclein siRNA program SOUTH SAN FRANCISCO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC…
ALEC — Frequently Asked Questions
What is the current share price of Alector, Inc. (ALEC)?
As of 2026-10-23 16:27 PDT, Alector, Inc. (ALEC) trades at $1.83 on NasdaqGS. Its 52-week range is $1.14 to $3.32.
What is the market capitalisation of ALEC?
Alector, Inc. (ALEC) has a market capitalisation of $204.33M on NasdaqGS.
What is the P/E ratio of ALEC?
ALEC trades at a trailing price-to-earnings (P/E) ratio of -1.68. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is -23.37.
Is ALEC a good stock to buy?
This page provides a data-driven analysis of Alector, Inc. (ALEC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.